Alendronate reduces serum TNFα and IL-1β, increases neutrophil counts, and improves bone mineral density and bone metabolism indices in patients with chronic idiopathic neutropenia (CIN)-associated osteopenia/osteoporosis

Journal of Bone and Mineral Metabolism

Volumn 22, Issue 6, 2004, Pages 577-587

  Papadaki, Helen A ^a   Tsatsanis, Christos ^a   Christoforidou, Anna ^a   Malliaraki, Niki ^a   Psyllaki, Maria ^a   Pontikoglou, Charis ^a   Miliaki, Maria ^a   Margioris, Andrew N ^a   Eliopoulos, George D ^a  

^a UNIVERSITY OF CRETE   (Greece)

Author keywords

Alendronate; Chronic idiopathic neutropenia (CIN); Interleukin 1 (IL 1 ); Osteocalcin; Osteopenia; Osteoporosis; Tumor necrosis factor alpha (TNF )

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; BIOCHEMICAL MARKER; COLLAGEN TYPE 1; CYTOKINE; DEOXYPYRIDINOLINE; INTERLEUKIN 1BETA; OSTEOCALCIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE MINERAL; CELL COUNT; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; IDIOPATHIC DISEASE; MACROPHAGE; MEASUREMENT; MONOCYTE; NEUTROPENIA; NEUTROPHIL; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; VOLUNTEER;

ADULT; AGED; ALENDRONATE; BIOLOGICAL MARKERS; BONE DENSITY; BONE DISEASES, METABOLIC; CHRONIC DISEASE; FEMALE; FEMUR NECK; HUMANS; INTERLEUKIN-1; LEUKOCYTE COUNT; MIDDLE AGED; NEUTROPENIA; NEUTROPHILS; OSTEOPOROSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 8744306865     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-004-0526-y     Document Type: Article

References (35)

1. Kyle RA, Linman JW (1968) Chronic idiopathic neutropenia: a newly recognised syndrome? N Engl J Med 279:1015-1019
2. Dale DC, Guerry D, Wewerka J, Bull J, Chusid M (1979) Chronic neutropenia. Medicine (Baltimore) 58:128-144
3. Haddy TB, Rana SR, Castro O (1999) Benign ethnic neutropenia: what is a normal absolute neutrophil count? J Lab Clin Med 133:15-22
4. Papadaki HA, Palmblad J, Eliopoulos GD (2001) Non-immune chronic idiopathic neutropenia of adult: an overview. Eur J Haematol 67:35-44
5. Papadaki HA, Eliopoulos GD (1998) Enhanced neutrophil extravasation may be a contributing factor in the determination of neutropenia in patients with chronic idiopathic neutropenia of adults. Eur J Haematol 61:272-277
6. Kyle RA (1980) Natural history of chronic idiopathic neutropenia. N Engl J Med 302:908-909
7. Papadaki HA, Eliopoulos GD (2002) An overview on the diagnosis, classification and differential diagnosis of chronic neutropenias. Haema 5:39-49
8. Papadaki HA, Eliopoulos GD, Coulocheri SA, Spyropoulou M, Stavropoulos-Giokas C (2001) Increased frequency of HLA-DKB1*1302 haplotype in patients with nonimmune chronic idiopathic neutropenia of adult. Blood 97:850-851
9. WHO Study Group (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Tech Rep Series 843:1-129
10. Papadaki HA, Margioris A, Miliaki M, Steriopoulos C, Valatas V, Eliopoulos GD (1999) Chronic idiopathic neutropenia of adults is associated with decreased bone mineral density and alterations in bone turnover biochemical markers. Eur J Haematol 62:311-316
11. Ammann P, Rizzoli R, Bonjour JP, Bourrin S, Meyer JM, Vassalli P, Garcia L (1997) Transgenic mice expressing soluble tumor necrosis factor-receptor are protected against bone loss caused by estrogen deficiency. J Clin Invest 99:1699-1703
12. Papadaki HA, Coulocheri SA, Eliopoulos GD (2000) Patients with chronic idiopathic neutropenia of adult have increased serum concentrations of inflammatory cytokines and chemokines. Am J Hematol 65:271-277
13. Papadaki HA, Eliopoulos AG, Kosteas T, Gemetzi C, Damianaki A, Koutala H, Bux J, Eliopoulos GD (2003) Impaired granulocytopoiesis in patients with chronic idiopathic neutropenia is associated with increased apoptosis of bone marrow myeloid progenitor cells. Blood 101:2591-2600
14. Fleisch H (1998) Bisphosphonates: mechanisms of action. Endocr Rev 19:80-100
15. Gucalp R, Theriault R, Gill I, Madajewcz S, Chapman R, Navari R, Ahmann F, Zelenakas K, Heffernan M, Knight RD (1994) Treatment of cancer-associated hypercalcemia: double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. Arch Intern Med 154: 1935-1944
16. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, Lipton A, Keller A, Ballester O, Kovacs M, Blacklock H, Bell R, Simeone JF, Reitsma DJ, Heffernan M, Seaman J, Knight RD (1998) Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol 16:593-602
17. Miller PD, Brown JP, Siris ES, Hoseyni MS, Axelson DM, Bekker PJ (1999) A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group. Am J Med 106:513-520
18. Cummings SR, Blank DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial. JAMA 280:2077-2082
19. Chailurkit L, Jongiaroenprasert W, Rungbunnapun S, Ongphiphanakul B, Sae-Tung S, Rajatanavin R (2003) Effect of alendronate on bone mineral density and bone turnover in Thai postmenopausal osteoporosis. J Bone Miner Metab 21:421-427
20. Marie PJ, Hott M, Launay JM, Graulet AM, Gueris J (1993) In vitro production of cytokines by bone surface-derived osteoblastic cells in normal and osteoporotic post-menopausal women: relationship with cell proliferation. J Clin Endocr Metab 77:824-830
21. Parfitt AM (1980) Morphologic basis of bone mineral measurements: transient and steady state effects of treatment in osteoporosis. Miner Electrolyte Metab 4:273-287
22. Ivey JL, Baylink DJ (1981) Postmenopausal osteoporosis: proposed roles of defective coupling and estrogen deficiency. Metab Bone Dis Relat Res 3:3-8
23. Hughes DE, Wright KR, Uy HL, Sasaki A, Yoneda T, Roodman GD, Mundy GR, Boyce BF (1995) Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10:1478-1487
24. Colucci S, Minielli V, Zambonin G, Grano M (1995) Etidronate inhibits osteoclast adhesion to bone surfaces but does not interfere with their specific recognition of single bone proteins. Ital J Miner Electrolyte Metab 9:159-164
25. Hughes DE, MacDonald BR, Russell RGG, Gowen M (1989) Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest 83:1930-1935
26. Sato M, Grasser W (1990) Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res 5:31-40
27. Cecchini MG, Felix R, Fleisch H, Cooper PH (1987) Effects of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. J Bone Miner Res 2:135-142
28. Cecchini MG, Fleisch H (1990) Bisphosphonates in vitro specifically inhibit, among the hematopoietic series, the development of the mouse mononuclear phagocyte lineage. J Bone Miner Res 5:1019-1027
29. Stevenson PH, Stevenson JR (1986) Cytotoxic and migration inhibitory effects of biphosphonates on macrophages. Calcif Tissue Int 38:227-233
30. Chambers TJ (1980) Diphosphonates inhibit bone resorption by macrophages in vitro. J Pathol 132:255-262
31. Bijvoet OL, Frijlink WB, Jie K, van der Linden H, Meijer CJ, Mulder H, van Paasen HC, Reitsma PH, te Velde J, de Vries E, van der Wey JP (1980) APD in Paget's disease of bone. Role of the mononuclear phagocyte system? Arthritis Rheum 23:1193-1204
32. Sansoni P, Passeri G, Fagnoni F, Mohagheghpour N, Snelli G, Brianti V, Engleman EG (1995) Inhibition of antigen-presenting cell function by alendronate in vitro. J Bone Miner Res 10:1719-1725
33. Pennanen N, Lapinjpli S, Urtti A, Monkkonen J (1995) Effect of liposomal and free bisphosphonates on the IL-1β, IL-6 and TNFα secretion from RAW 264 cells in vitro. Pharmacol Res 12:916-922
34. Li M, Mosekilde L, Sogaard CH, Thomsen JS, Wronski TJ (1995) Parathyroid hormone monotherapy and co-therapy with antiresorptive agents restores vertebral bone mass and strength in aged ovariectomized rats. Bone 16:629-635
35. Cantatore FP, Acquista CA, Pipitone V (1999) Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate. J Rheumatol 26:2318-2323